Spots Global Cancer Trial Database for A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
Official Title: A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Study ID: NCT02407054
Conditions
Study Description
Brief Summary: The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as LY3023414 in combination with enzalutamide in men with prostate cancer.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
Urology Centers of Alabama, P.C., Homewood, Alabama, United States
Highlands Oncology Group, Fayetteville, Arkansas, United States
Prostate Oncology Specialists, Marina Del Rey, California, United States
Sharp Memorial Hospital, San Diego, California, United States
Florida Cancer Specialists, Fort Myers, Florida, United States
Florida Cancer Specialists North, Saint Petersburg, Florida, United States
Florida Cancer Specialists East, West Palm Beach, Florida, United States
Ingalls Memorial Hospital, Harvey, Illinois, United States
Fort Wayne Oncology & Hematology, Fort Wayne, Indiana, United States
Indiana Cancer Pavilion, Indianapolis, Indiana, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Minnesota Oncology/Hematology PA, Minneapolis, Minnesota, United States
Urology Cancer Center, Omaha, Nebraska, United States
Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
Garden State Urology, Morristown, New Jersey, United States
Delaware Valley Urology, Voorhees, New Jersey, United States
Associated Medical Professionals of NY, Syracuse, New York, United States
Oncology Hematology Care Inc, Cincinnati, Ohio, United States
Cleveland Clinic Foundation, Cleveland, Ohio, United States
Oregon Urology Institute, Springfield, Oregon, United States
Northwest Cancer Specialists PC, Tualatin, Oregon, United States
Urological Associates of Lancaster, Lancaster, Pennsylvania, United States
Univ of Pittsburgh Cancer Inst. (UPCI), Pittsburgh, Pennsylvania, United States
Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States
Sarah Cannon Research Institute SCRI, Nashville, Tennessee, United States
Tennessee Oncology PLLC, Nashville, Tennessee, United States
Urology Associates, Nashville, Tennessee, United States
Southwestern Medical Center - Dallas, Dallas, Texas, United States
Texas Oncology-Baylor Charles A. Sammons Cancer Center, Fort Worth, Texas, United States
Texas Oncology-Memorial City, Houston, Texas, United States
US Oncology, The Woodlands, Texas, United States
University of Virginia Health System, Charlottesville, Virginia, United States
Virginia Cancer Specialists, Fairfax, Virginia, United States
Virginia Oncology Associates, Norfolk, Virginia, United States
Swedish Medical Center, Seattle, Washington, United States
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Contact Details
Name: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Affiliation: Eli Lilly and Company
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
